As of June 30, 2019, BioSpecifics has received over $178.0 million from partnerships under the XIAFLEX franchise.

BioSpecifics is partnered with Endo for CCH (marketed in the U.S. under the trade name XIAFLEX) and Endo continues to manage the research and development of XIAFLEX and CCH for their licensed indications. Endo expects mid-to-high teens percentage range growth for XIAFLEX revenue in 2019.

Under the terms of the partnership agreement, BioSpecifics is eligible for future low double-digit royalties as a percentage of worldwide net sales (independent of clinical indication, territory and sales volume), additional mark-up on cost of goods sold (COGS) in U.S. and sales made in any other country where Endo sells the product directly or through affiliate sublicensees and modest milestones for additional indications and regulatory submissions worldwide. Currently licensed rights cover the indications of Dupuytren's contracture, Peyronie's disease, frozen shoulder, cellulite, lateral hip fat, plantar fibromatosis and human and canine lipomas.

BioSpecifics has entered into distinct in-licensing and royalty agreements in respect of indications currently marketed and under development. It is company policy not to announce publicly royalty rates for potential future indications under development before commercialization. It is important to emphasize that in-licensing royalty rates vary from indication to indication and it should not be assumed that the in-licensing royalty rates for potential future indications will be the same as those for currently marketed indications.